Yes, Pluvicto Can Cause Anemia
Pluvicto (lutetium-177 vipivotide tetraxetan) causes anemia as a significant and well-documented adverse effect, with Grade 3 or 4 anemia occurring in 7-15% of patients. This is explicitly stated in the FDA drug label and confirmed across multiple clinical trials 1.
Severity and Incidence
The FDA label clearly warns that Pluvicto can cause severe and life-threatening myelosuppression, including anemia 1. The incidence varies by study:
- PSMAfore trial: Grade 3-4 decreased hemoglobin occurred in 7% of patients treated with Pluvicto 1
- VISION trial: Grade 3-4 decreased hemoglobin occurred in 15% of patients 1, 2
- Overall incidence: Decreased hemoglobin (any grade) occurred in 65-67% of patients across pooled safety data 1
The NCCN guidelines specifically identify anemia as one of the grade ≥3 adverse events that occurs "significantly higher" in patients receiving Pluvicto compared to standard of care alone 3, 4.
Mechanism and Timing
Anemia from Pluvicto results from radiation-induced bone marrow suppression. The radiopharmaceutical delivers beta-particle radiation to PSMA-expressing cells and surrounding tissues, including bone marrow 3.
Hematological nadirs typically occur 4-8 weeks after administration, though monitoring should begin earlier 1.
Clinical Management Algorithm
Before each cycle:
During treatment:
- Perform weekly CBCs from 2 weeks after administration until recovery from cytopenias 1
- Monitor more frequently if hemoglobin drops significantly
Dose modifications based on severity 1:
- Grade 3 anemia (hemoglobin 6.5-8.0 g/dL): Withhold Pluvicto until recovery to Grade ≤1, then resume at reduced dose (6.66 GBq)
- Grade 4 anemia (hemoglobin <6.5 g/dL): Withhold until recovery, then resume at reduced dose or permanently discontinue based on clinical judgment
- Recurrent Grade 3-4: Permanently discontinue
Supportive care:
- Red blood cell transfusions as needed per institutional guidelines 1
- Consider recombinant erythropoietin according to local protocols 1
Critical Warnings
The FDA label documents fatal outcomes related to myelosuppression, including deaths from bone marrow failure, intracranial hemorrhage, and subdural hematoma associated with cytopenias 1. One death specifically occurred due to bone marrow failure during long-term follow-up in the PSMAfore study 1.
Pancytopenia (affecting all blood cell lines including red blood cells) occurred in 1.1% of patients in the VISION trial, with two fatal events 1.
Real-World Context
Recent real-world data confirms these findings, with Grade ≥3 anemia occurring in 13 of 35 evaluable patients (37%) receiving subsequent therapy after Pluvicto, requiring hematologic support in many cases 6. Another real-world analysis identified anemia as one of the most commonly reported adverse events in post-marketing surveillance 7.
The cumulative radiation dose to bone marrow from the standard 6-cycle regimen (44.4 GBq total) is substantial, with estimated absorbed doses of 1.5-2.5 Gy to red marrow 1, explaining the high incidence of hematologic toxicity.